Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Stopped Based on preliminary safety data.

Conditions

• Duchenne Muscular Dystrophy

Interventions

• BIOLOGICAL: ACE-031 0.5 mg/kg q4wk
• BIOLOGICAL: ACE-031 1.0 mg/kg q2wk
• OTHER: Placebo

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA